Amylyx Pharmaceuticals to Submit New Drug Application for AMX0035
Following the promising results of the CENTAUR trial, Amylyx Pharmaceuticals has announced a plan to seek FDA approval for the drug AMX0035 for the treatment of ALS.
Read moreSean M. Healey & AMG Center for ALS
News & Events
Massachusetts General Hospital reports on news from the Sean M. Healey & AMG Center for ALS at Mass General on clinical trials, progress in research, and recognition for clinical excellence.
News
Recent Media Coverage
View All
ALS News TodaySeptember | 28 | 2021
Early Access to CNM-Au8 Given to Patients Ineligible for HEALEY Trial
ALS News Today covers efforts to enroll additional people with ALS in expanded access programs for an experimental ALS treatment, even when they do not qualify for participation in a clinical trial.
BioSpaceSeptember | 13 | 2021
Amylyx Pharmaceuticals Donates CENTAUR Clinical Trial Data and Participant Samples
Amylyx Pharmaceuticals has donated data and biological samples generated by the CENTAUR clinical trial that evaluated the safety and efficacy of AMX0035 in participants with amyotrophic lateral sclerosis (ALS). The donations will be managed by groups at the Healey Center for ALS and the Barrow Neurological Institute.
Make a Difference for the Healey Center
Join our quest to discover life-saving therapies for individuals who are affected by ALS. The key to our success is our dedication to collaboration. At the Sean M. Healey and AMG Center for ALS at Mass General, we partner with the best clinician-scientists, our patients and friends like you to turn laboratory successes into promising therapies.